How Investors May Respond To Cencora (COR) Deepening Its Rare Disease Services Through Curant Collaboration [Yahoo! Finance]
Cencora, Inc. (COR)
Last cencora, inc. earnings: 4/30 06:30 am
Check Earnings Report
US:NYSE Investor Relations:
investors.coresite.com/investor-overview
Company Research
Source: Yahoo! Finance
capabilities with Curant Rare's specialty pharmacy and patient-engagement services to support rare disease therapies. This partnership is designed to give rare disease drug developers integrated access to real-world evidence, patient-reported outcomes and market access support, aiming to smooth complex regulatory and access hurdles. With growing focus on specialty and rare disease support, we'll explore how this collaboration shapes Cencora's broader investment narrative. AI is about to change healthcare. These 110 stocks are working on everything from early diagnostics to drug discovery . The best part - they are all under $10b in market cap - there's still time to get in early. To own Cencora, you have to be comfortable with a low-margin, scale-driven distributor that is leaning harder into higher-value specialty services. The Curant Rare collaboration fits that story neatly, reinforcing Cencora's push into rare disease support alongside moves like OneOncology and World Cour
Show less
Read more
Impact Snapshot
Event Time:
COR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COR alerts
High impacting Cencora, Inc. news events
Weekly update
A roundup of the hottest topics
COR
News
- Cencora (NYSE:COR) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.MarketBeat
- Chief Executives for Corporate Purpose Announces Covista Chairman and CEO Steve Beard, Cencora Inc. Former Executive Chair Steven H. Collis, and Ann Fairchild, interim President and CEO of Siemens USA Joining Board of Directors [Yahoo! Finance]Yahoo! Finance
- Cencora (NYSE:COR) was upgraded by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from a "hold (c+)" rating to a "buy (b)" rating.MarketBeat
- Cencora (COR) Stock Trades Up, Here Is Why [Yahoo! Finance]Yahoo! Finance
- Cencora (NYSE:COR) had its price target lowered by analysts at Evercore ISI from $440.00 to $420.00. They now have an "outperform" rating on the stock.MarketBeat
COR
Earnings
- 2/4/26 - Beat
COR
Sec Filings
- 2/10/26 - Form 424B5
- 2/10/26 - Form 8-K
- 2/4/26 - Form 10-Q
- COR's page on the SEC website